{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:56:49Z","timestamp":1786993009293,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A5A2025964"],"award-info":[{"award-number":["2018R1A5A2025964"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019M3C7A1031867"],"award-info":[{"award-number":["2019M3C7A1031867"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jns.2022.120512","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:27:23Z","timestamp":1669595243000},"page":"120512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Serum C3 complement levels predict prognosis and monitor disease activity in Guillain-Barr\u00e9 syndrome"],"prefix":"10.1016","volume":"444","author":[{"given":"Young Gi","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woohee","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Woo","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Eun","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Jun","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Nam","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Yeong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Joon","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3988\/jcn.2021.17.2.257","article-title":"Epidemiological features and economic burden of Guillain-Barre Syndrome in South Korea: A nationwide population-based study","volume":"17","author":"Kim","year":"2021","journal-title":"J Clin Neurol"},{"issue":"5","key":"10.1016\/j.jns.2022.120512_bb0010","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1212\/WNL.0000000000013139","article-title":"Predicting outcome in Guillain-Barre Syndrome: international validation of the modified erasmus GBS outcome score","volume":"vol. 98","author":"Doets","year":"2022","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2022.120512_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barre syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2022.120512_bb0020","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2022.120512_bb0025","series-title":"Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group, (0140\u20136736 (Print))","author":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome","year":"1997"},{"key":"10.1016\/j.jns.2022.120512_bb0030","series-title":"A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barr\u00e9 syndrome, (1526-632X (Electronic))","author":"Pritchard","year":"2003"},{"key":"10.1016\/j.jns.2022.120512_bb0035","series-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: randomised trial, (1474-547X (Electronic))","author":"van Koningsveld","year":"2004"},{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0040","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","article-title":"Original research: Second IVIg course in Guillain-Barre syndrome with poor prognosis: the non-randomised ISID study","volume":"91","author":"Verboon","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.jns.2022.120512_bb0045","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/jnnp.2006.102731","article-title":"Treatment of Guillain-Barr\u00e9 syndrome with mycophenolate mofetil: a pilot study","volume":"78","author":"Garssen","year":"2007","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2022.120512_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"econd intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"The Lancet Neurol."},{"key":"10.1016\/j.jns.2022.120512_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"Aguirre","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.jns.2022.120512_bb0060","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2022.120512_bb0065","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/1352458516669002","article-title":"Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"23","author":"Hakobyan","year":"2017","journal-title":"Mult. Scler."},{"issue":"Pt 6","key":"10.1016\/j.jns.2022.120512_bb0070","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/brain\/awq085","article-title":"Complement regulator factor H as a serum biomarker of multiple sclerosis disease state","volume":"133","author":"Ingram","year":"2010","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.jns.2022.120512_bb0075","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/ana.26226","article-title":"Complement activation is a prominent feature of MOGAD","volume":"90","author":"Keller","year":"2021","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2022.120512_bb0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jneuroim.2014.09.005","article-title":"Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood","volume":"276","author":"Mantovani","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"1\u20132","key":"10.1016\/j.jns.2022.120512_bb0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2014.07.001","article-title":"Complement activation in patients with neuromyelitis optica","volume":"274","author":"Nytrova","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.jns.2022.120512_bb0090","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/ene.14500","article-title":"Changes in serum complements and their regulators in generalized myasthenia gravis","volume":"28","author":"Ozawa","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"8","key":"10.1016\/j.jns.2022.120512_bb0095","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/brain\/awab102","article-title":"Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders","volume":"144","author":"Takai","year":"2021","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jns.2022.120512_bb0100","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000119","article-title":"Complement activity is associated with disease severity in multifocal motor neuropathy","volume":"2","author":"Vlam","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.jns.2022.120512_bb0105","series-title":"Safety and Efficacy of Eculizumab in Anti-Acetylcholine Receptor Antibody-Positive Refractory Generalised Myasthenia gravis (REGAIN): A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study, (1474\u20134465 (Electronic))","author":"Howard","year":"2017"},{"issue":"7","key":"10.1016\/j.jns.2022.120512_bb0110","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.jns.2022.120512_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0006-8993(87)90572-5","article-title":"Complement depletion suppresses Lewis rat experimental allergic neuritis","volume":"419","author":"Feasby","year":"1987","journal-title":"Brain Res."},{"issue":"15","key":"10.1016\/j.jns.2022.120512_bb0120","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","article-title":"Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers","volume":"27","author":"Susuki","year":"2007","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.jns.2022.120512_bb0125","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.expneurol.2011.11.039","article-title":"Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies","volume":"233","author":"Susuki","year":"2012","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0165-5728(95)00006-N","article-title":"Complement depletion affects demyelination and inflammation in experimental allergic neuritis","volume":"58","author":"Vriesendorp","year":"1995","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ana.20546","article-title":"Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome","volume":"58","author":"Halstead","year":"2005","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.jns.2022.120512_bb0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1529-8027.2008.00181.x","article-title":"C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome","volume":"13","author":"Halstead","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"issue":"6","key":"10.1016\/j.jns.2022.120512_bb0145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","article-title":"Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial","volume":"17","author":"Misawa","year":"2018","journal-title":"The Lancet Neurol."},{"issue":"5","key":"10.1016\/j.jns.2022.120512_bb0150","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1172\/JCI113231","article-title":"Activation of terminal components of complement in patients with Guillain-Barr\u00e9 syndrome and other demyelinating neuropathies","volume":"80","author":"Koski","year":"1987","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.jns.2022.120512_bb0155","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.4049\/jimmunol.177.6.4211","article-title":"Mannose-binding lectin contributes to the severity of Guillain-Barr\u00e9 syndrome","volume":"177","author":"Geleijns","year":"2006","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.jns.2022.120512_bb0160","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrneurol.2014.138","article-title":"Guillain-Barr\u00e9 and Miller Fisher syndromes--new diagnostic classification","volume":"10","author":"Wakerley","year":"2014","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2022.120512_bb0165","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mus.22298","article-title":"Sensory Guillain-Barr\u00e9 syndrome and related disorders: an attempt at systematization","volume":"45","author":"Uncini","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2022.120512_bb0170","series-title":"Electrophysiological Diagnosis of Guillain-Barr\u00e9 Syndrome Subtype: Could a Single Study Suffice?, (1468-330X (Electronic))","author":"Rajabally","year":"2015"},{"issue":"1","key":"10.1016\/j.jns.2022.120512_bb0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41598-019-57366-y","article-title":"High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis","volume":"10","author":"Choi","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0180","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamaneurol.2016.4480","article-title":"Association of Albumin levels with outcome in intravenous immunoglobulin-treated Guillain-Barre Syndrome","volume":"74","author":"Fokkink","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.jns.2022.120512_bb0185","article-title":"Neutrophil\u2013lymphocyte ratio and response to plasmapheresis in Guillain\u2013Barr\u00e9 syndrome: a prospective observational study","volume":"56","author":"Hashim","year":"2020","journal-title":"The Egyptian J. Neurol. Psychiatr. Neurosurg."},{"issue":"5","key":"10.1016\/j.jns.2022.120512_bb0190","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/ana.21737","article-title":"Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barre syndrome","volume":"66","author":"Kuitwaard","year":"2009","journal-title":"Ann. Neurol."},{"issue":"9","key":"10.1016\/j.jns.2022.120512_bb0195","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1590\/0004-282X20160132","article-title":"Analysis of the albumin level, neutrophil-lymphocyte ratio, and platelet-lymphocyte ratio in Guillain-Barre syndrome","volume":"74","author":"Ozdemir","year":"2016","journal-title":"Arq. Neuropsiquiatr."},{"issue":"12","key":"10.1016\/j.jns.2022.120512_bb0200","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/jnnp-2020-323960","article-title":"Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barre syndrome","volume":"91","author":"Yamagishi","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2022.120512_bb0205","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41983-020-0154-z","article-title":"Neutrophil\u2013lymphocyte ratio and response to plasmapheresis in Guillain\u2013Barr\u00e9 syndrome: a prospective observational study","volume":"56","author":"Hashim","year":"2020","journal-title":"The Egyptian J. Neurol. Psychiatr. Neurosurg."},{"issue":"8","key":"10.1016\/j.jns.2022.120512_bb0210","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/00207454.2017.1418342","article-title":"The clinical significance of neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio in Guillain-Barre syndrome","volume":"128","author":"Huang","year":"2018","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.jns.2022.120512_bb0215","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp-2020-323899","article-title":"Serum neurofilament light chain predicts long-term prognosis in Guillain-Barre syndrome patients","volume":"92","author":"Martin-Aguilar","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.jns.2022.120512_bb0220","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12974-020-01737-0","article-title":"Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barre syndrome","volume":"17","author":"Altmann","year":"2020","journal-title":"J. Neuroinflammation"},{"issue":"5","key":"10.1016\/j.jns.2022.120512_bb0225","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2022.120512_bb0230","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/STROKEAHA.120.031715","article-title":"Increased serum complement C3 Levels Are Associated With Adverse Clinical Outcomes After Ischemic Stroke","volume":"52","author":"Yang","year":"2021","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jns.2022.120512_bb0235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13075-021-02433-x","article-title":"Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis","volume":"23","author":"Chen","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0240","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cei.12952","article-title":"Production of complement components by cells of the immune system","volume":"188","author":"Lubbers","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jns.2022.120512_bb0245","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.jns.2022.120512_bb0250","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0255","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s40620-017-0445-3","article-title":"Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome","volume":"31","author":"Crnogorac","year":"2018","journal-title":"J Nephrol"},{"issue":"4","key":"10.1016\/j.jns.2022.120512_bb0260","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000508747","article-title":"HyperCKemia in Guillain-Barr\u00e9 Syndrome","volume":"83","author":"Choi","year":"2020","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0265","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3988\/jcn.2014.10.2.94","article-title":"Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barr\u00e9 syndrome in Korea: a nationwide multicenter study","volume":"10","author":"Kim","year":"2014","journal-title":"J Clin Neurol"},{"issue":"1","key":"10.1016\/j.jns.2022.120512_bb0270","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1038\/s41598-022-14184-z","article-title":"Old age and multiple comorbidity are associated with delayed diagnosis of Guillain-Barre syndrome","volume":"12","author":"Kim","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.jns.2022.120512_bb0275","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1046\/j.1365-3083.1998.00386.x","article-title":"High-dose intravenous immunoglobulin treatment activates complement in vivo","volume":"48","author":"Mollnes","year":"1998","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.jns.2022.120512_bb0280","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2003-05-1530","article-title":"Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level","volume":"103","author":"Lutz","year":"2004","journal-title":"Blood"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X22003744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:00:42Z","timestamp":1758384042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X22003744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":56,"alternative-id":["S0022510X22003744"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2022.120512","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum C3 complement levels predict prognosis and monitor disease activity in Guillain-Barr\u00e9 syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2022.120512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120512"}}